Flicker M, Neumann M
Wien Med Wochenschr. 1983 Aug 31;133(15-16):397-402.
This report gives a comparison of two polychemotherapeutic regimen: Vincristin-Adriamycin-Cyclophosphamide (VAC) versus Vinblastin, Methotrexate, Fluoro Uracil, Cyclophosphamide (Israel-Karrer-Sighart regimen). 35 patients have been treated with VAC, 27 with IKS, some of them received additional irradiation. Response was quite similar in both regimens, survival was significantly increased for patients treated with VAC (49 weeks medial survival time versus 31 weeks). Best results were obtained in combination with intermittent radiotherapy (so called "sandwich-method"), survival time in this treatment had been 73 weeks. Side effects of the chemotherapy were tolerable and not severe. VAC in extensive disease alone and in limited disease in addition to radiotherapy can, therefore, be recommended in outdoor-patients treatment in small cell carcinoma of the lung.
长春新碱-阿霉素-环磷酰胺（VAC）方案与长春碱、甲氨蝶呤、氟尿嘧啶、环磷酰胺方案（以色列-卡勒-西哈特方案）。35例患者接受了VAC方案治疗，27例接受了IKS方案治疗，其中一些患者还接受了额外的放疗。两种方案的反应相当相似，接受VAC方案治疗的患者生存率显著提高（中位生存时间为49周，而另一种方案为31周）。联合间歇性放疗（即所谓的“三明治法”）取得了最佳效果，这种治疗方式的生存时间为73周。化疗的副作用是可耐受的，并不严重。因此，对于门诊治疗的小细胞肺癌患者，VAC方案可用于广泛期疾病的单独治疗以及局限期疾病放疗后的辅助治疗。
